Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on August 3, 2026

Aug. 3, 2026

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Indeterminate GlobeNewswire

Aug. 3, 2026

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

Indeterminate GlobeNewswire

Aug. 3, 2026

Veritasium Goes Behind the Scenes at Kraig Biocraft Laboratories to Explore the Future of Commercial Spider Silk

Indeterminate GlobeNewswire

Aug. 3, 2026

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Indeterminate GlobeNewswire

Aug. 3, 2026

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Indeterminate GlobeNewswire

Aug. 3, 2026

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Indeterminate GlobeNewswire

Aug. 3, 2026

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Indeterminate GlobeNewswire

Aug. 3, 2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Indeterminate GlobeNewswire

Aug. 3, 2026

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Indeterminate GlobeNewswire

Aug. 3, 2026

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Indeterminate GlobeNewswire

Aug. 3, 2026

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Indeterminate GlobeNewswire

Aug. 3, 2026

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Indeterminate GlobeNewswire

Aug. 3, 2026

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Indeterminate GlobeNewswire

Aug. 3, 2026

PLNT Class Action Notice: Planet Fitness Hit with Securities Fraud Lawsuit over Membership Growth Misrepresentations – Investors Urged to Contact BFA Law by September 14 Deadline

Indeterminate GlobeNewswire

Aug. 3, 2026

Supernus Announces Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Aug. 3, 2026

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indeterminate GlobeNewswire

Aug. 3, 2026

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Indeterminate GlobeNewswire

Aug. 3, 2026

BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden

Indeterminate GlobeNewswire

Aug. 3, 2026

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Indeterminate GlobeNewswire

Aug. 3, 2026

NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer

Indeterminate GlobeNewswire